PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Sara A. Hurvitz, MD, FACP - Drug-Induced Interstitial Lung Disease and Breast Cancer: Knowing the Odds and Managing the Risk
Visit https://www.peervoice.com/XPV860 to view the entire programme with slides. After completing “Sara A. Hurvitz, MD, FACP - Drug-Induced Interstitial Lung Disease and Breast Cancer: Knowing the Odds and Managing the Risk”, participants will be able to: Across clinical studies of HER2-targeted therapies for HER2-positive breast cancer, assess the incidence rates of drug-induced interstitial lung disease (ILD); Formulate practical approaches to optimise the monitoring for drug-induced ILD in patients with HER2-positive breast cancer; and Use effective, evidence-based strategies for managing drug-induced ILD in patients with HER2-positive breast cancer.